# Peter MacCallum Cancer Centre

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/peter-maccallum-cancer-centre/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 51.9 |
| Citations | 3,931,648 |
| City | Melbourne |
| Country | AU |
| Description | Peter MacCallum Cancer Centre is a research organisation in Melbourne, AU. OpenAlex records 24,570 works and 3,931,648 citations for it. 4,446 researchers list it as their most recent affiliation. |
| Homepage | http://www.petermac.org/ |
| OpenAlex ID | https://openalex.org/I2800555584 |
| Region | Victoria |
| Researchers | 4,446 |
| ROR ID | https://ror.org/02a8bt934 |
| Type | healthcare |
| Works | 24,570 |

## University collaborators

- [The University of Melbourne](https://scholariq.org/institutions/the-university-of-melbourne/)

## University papers

Showing 12 of 104.

- [<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1](https://scholariq.org/papers/i-lmo2-i-associated-clonal-t-cell-proliferation-in-two-patients-after-gene/)
- [The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014](https://scholariq.org/papers/the-evaluation-of-tumor-infiltrating-lymphocytes-tils-in-breast-cancer/)
- [Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study](https://scholariq.org/papers/nivolumab-in-patients-with-metastatic-dna-mismatch-repair-deficient-or/)
- [Detection and localization of surgically resectable cancers with a multi-analyte blood test](https://scholariq.org/papers/detection-and-localization-of-surgically-resectable-cancers-with-a-multi-analyte/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors](https://scholariq.org/papers/kras-sup-g12c-sup-inhibition-with-sotorasib-in-advanced-solid-tumors/)
- [Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters](https://scholariq.org/papers/lineage-specific-genome-architecture-links-enhancers-and-non-coding-disease/)
- [The 2019 World Health Organization classification of tumours of the breast](https://scholariq.org/papers/the-2019-world-health-organization-classification-of-tumours-of-the-breast/)

## University researchers

- [Michael Michael](https://scholariq.org/researchers/michael-michael/)
- [Kate L. Graham](https://scholariq.org/researchers/kate-l-graham/)
- [Peadar S. Waters](https://scholariq.org/researchers/peadar-s-waters/)
- [Jane Stewart](https://scholariq.org/researchers/jane-stewart/)
- [Amelia Hyatt](https://scholariq.org/researchers/amelia-hyatt/)
- [Marian Lieschke](https://scholariq.org/researchers/marian-lieschke/)
- [Peter F. Gearing](https://scholariq.org/researchers/peter-f-gearing/)
- [Ashleigh Bradford](https://scholariq.org/researchers/ashleigh-bradford/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.